martes, 31 de octubre de 2017

Journal for ImmunoTherapy of Cancer | Immunotherapy Biomarkers

Journal for ImmunoTherapy of Cancer | Immunotherapy Biomarkers

Biomed Central

JITC logo

Immunotherapy Biomarkers

Section edited by Lisa H. Butterfield, PhD
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
Previous Page Page 1 of 2 Next Page

    Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

    Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the de...
    Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper and David L. Rimm
    Journal for ImmunoTherapy of Cancer 2017 5:81
    Published on: 17 October 2017

    Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

    There is an unmet need to determine factors predictive of clinical benefit, to guide therapeutic sequencing and selection in metastatic RCC (mRCC). We evaluated clinical factors such as the neutrophil lymphocy...
    Ghayathri Jeyakumar, Seongho Kim, Naresh Bumma, Craig Landry, Cynthia Silski, Stacey Suisham, Brenda Dickow, Elisabeth Heath, Joseph Fontana and Ulka Vaishampayan
    Journal for ImmunoTherapy of Cancer 2017 5:82
    Published on: 17 October 2017

    Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

    Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to...
    Philip Friedlander, Karl Wassmann, Alan M. Christenfeld, David Fisher, Chrisann Kyi, John M. Kirkwood, Nina Bhardwaj and William K. Oh
    Journal for ImmunoTherapy of Cancer 2017 5:67
    Published on: 15 August 2017

    Differential phenotypes of memory CD4 and CD8 T cells in the spleen and peripheral tissues following immunostimulatory therapy

    Studies assessing immune parameters typically utilize human PBMCs or murine splenocytes to generate data that is interpreted as representative of immune status. Using splenocytes, we have shown memory CD4-T ce...
    Gail D. Sckisel, Annie Mirsoian, Christine M. Minnar, Marka Crittenden, Brendan Curti, Jane Q. Chen, Bruce R. Blazar, Alexander D. Borowsky, Arta M. Monjazeb and William J. Murphy
    Journal for ImmunoTherapy of Cancer 2017 5:33
    Published on: 18 April 2017

    Immunotherapy biomarkers 2016: overcoming the barriers

    This report summarizes the symposium, ‘Immunotherapy Biomarkers 2016: Overcoming the Barriers’, which was held on April 1, 2016 at the National Institutes of Health in Bethesda, Maryland. The symposium, cospon...
    James L. Gulley, Jay A. Berzofsky, Marcus O. Butler, Alessandra Cesano, Bernard A. Fox, Sacha Gnjatic, Sylvia Janetzki, Shyam Kalavar, Vaios Karanikas, Samir N. Khleif, Ilan Kirsch, Peter P. Lee, Cristina Maccalli, Holden Maecker, Jeffrey Schlom, Barbara Seliger…
    Journal for ImmunoTherapy of Cancer 2017 5:29
    Published on: 21 March 2017

    Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

    Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (...
    James W. Smithy, Lauren M. Moore, Vasiliki Pelekanou, Jamaal Rehman, Patricia Gaule, Pok Fai Wong, Veronique M. Neumeister, Mario Sznol, Harriet M. Kluger and David L. Rimm
    Journal for ImmunoTherapy of Cancer 2017 5:25
    Published on: 21 March 2017

    Gene expression markers of Tumor Infiltrating Leukocytes

    Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the in...
    Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L. Disis, Melissa A. Geller, Kunle Odunsi, Joseph Beechem and Steven P. Fling
    Journal for ImmunoTherapy of Cancer 2017 5:18
    Published on: 21 February 2017

    Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

    Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-depend...
    Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley and Jeffrey Schlom
    Journal for ImmunoTherapy of Cancer 2017 5:20
    Published on: 21 February 2017

    Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

    Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor. In this context, we recently reported on the levels...
    Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez and Constantin N. Baxevanis
    Journal for ImmunoTherapy of Cancer 2016 4:75
    Published on: 15 November 2016
  10. REVIEW

    Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

    Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibi...
    Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield and Magdalena Thurin
    Journal for ImmunoTherapy of Cancer 2016 4:76
    Published on: 15 November 2016
  11. REVIEW

    Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations

    There is growing recognition that immunotherapy is likely to significantly improve health outcomes for cancer patients in the coming years. Currently, while a subset of patients experience substantial clinical...
    Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield and Magdalena Thurin
    Journal for ImmunoTherapy of Cancer 2016 4:77
    Published on: 15 November 2016

    Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients

    Preclinical studies suggest a synergistic effect between radiation, immunotherapy and anti-angiogenic therapy, although the mechanisms are unclear. Angiogenic cytokines are known to affect the immune system, a...
    Vishwajith Sridharan, Danielle N. Margalit, Stephanie A. Lynch, Mariano Severgnini, F. Stephen Hodi, Robert I. Haddad, Roy B. Tishler and Jonathan D. Schoenfeld
    Journal for ImmunoTherapy of Cancer 2016 4:32
    Published on: 21 June 2016

    Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial

    Depletion of CD25+ Tregs improves anti-tumor immunity in preclinical models. Denileukin diftitox is a recombinant fusion protein of human IL-2 and diptheria toxin fragment that also can kill CD25+ T cells. Prior ...
    Jason J. Luke, Yuanyuan Zha, Karen Matijevich and Thomas F. Gajewski
    Journal for ImmunoTherapy of Cancer 2016 4:35
    Published on: 21 June 2016

No hay comentarios:

Publicar un comentario